UK earnings, trading statements calendar - next 7 days
UK earnings, trading statements calendar - next 7 days
Read moreMon, 13th Dec 2010 18:06
UK earnings, trading statements calendar - next 7 days
Read moreTRADING UPDATES: Symphony Environmental's India foray; Panthera drills
Read moreTRADING UPDATES: Yellow Cake fundraises; Mercia Asset invests
Read more(Sharecast News) - Cell-based therapeutic specialist ReNeuron has entered a collaboration agreement with University College London (UCL), it announced on Tuesday, to conduct research into the generation of immune cells from induced pluripotent stem cells (iPSCs), for anti-cancer cell therapies.
Read more(Sharecast News) - Reneuron Group revealed on Thursday that non-executive director Barbara Staehelin had acquired 43,000 ordinary shares in the AIM-listed cell-based therapeutics developer.
Read moreDIRECTOR DEALINGS: Inspiration Healthcare exec sells 135,000 shares
Read moreTRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru
Read more(Sharecast News) - Cell-based therapeutics developer ReNeuron Group said on Monday that the first UK subject had been treated at the Oxford Eye Hospital as part of its phase 2a clinical evaluations for the treatment of retinitis pigmentosa (RP) - an inherited, degenerative eye disease.
Read more(Sharecast News) - Exosome therapeutics developer ReNeuron announced positive data on Monday that it said provided "clear preclinical proof-of-concept" that its novel exosome drug delivery technology could effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.
Read moreIN BRIEF: ReNeuron gets positive results from exosome drug data
Read moreAIM WINNERS & LOSERS: Cadence rises on Amapa "landmark"; ASOS dives
Read moreTRADING UPDATES: Sensyne revenue jumps; Stranger Holdings loss narrows
Read more(Sharecast News) - Cell-based therapeutics developer ReNeuron Group updated the market on its phase 2a clinical evaluations for the treatment of the inherited, degenerative eye disease retinitis pigmentosa on Friday, confirming that it had received regulatory approval to restart the study in all geographies.
Read moreUK shareholder meetings calendar - next 7 days
Read moreReNeuron taps Oxford Biomedica executive Catherine Isted as CFO
Read more